Product Reports Resources Pricing Login Book a demo

MorphoSys

Biotech & Life Sciences · Planegg, Germany · Founded 1992 · IPO 2018

Biotechnology company focused on the research and development of fully human antibodies

Valuation $2.72B
Revenue $262M
Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue
Knowledge graph
News Novartis pays Antares Therapeutics $105M to hunt new cancer drugs Jun 25, 2026

Talent graph

MorphoSys's talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

9 investors on MorphoSys's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 1 investor entered at this stage
Atlas Venture
Series A 4 investors entered at this stage
Genentech
Third Rock Ventures
The Column Group
Venrock
Series B+ 4 investors entered at this stage
Max Planck Society
Max Planck Innovation
Max Planck Institute for Biological Intelligence
Max Planck Institute of Biochemistry

Global footprint

Where MorphoSys has talent and traffic

Workforce by country
8 countries with
team presence
🇩🇪 Germany79.2%
🇺🇸 United States16.8%
🇨🇭 Switzerland1.8%
🇦🇷 Argentina0.6%
🇮🇳 India0.6%
Top 5 of 8 shown
Web traffic by country
450 monthly visits
across markets
🇺🇸 United States66.7%
🇬🇪 Georgia22.2%
Top 2 markets shown

Patent intelligence

$321M patent portfolio · 152 active families

Estimated portfolio value
$321M
11.8% of market cap · 2.6× larger than top peer Five Prime Therapeutics ($123M)
152 active patent families
Where MorphoSys innovates Anti antibodyAntiendomysial antibodiesBiochemistryDiseaseEnzyme

Where MorphoSys concentrates vs peers

Each axis is a top-10 topic across MorphoSys and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

MorphoSys's 4 investments and acquisitions.

Every disclosed deal where MorphoSys appeared as a backer or acquirer, 2010–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

4 deals across MorphoSys's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        MorphoSys's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        4 of 4 deals

        Market sentiment

        What the market is saying about MorphoSys

        An AI-synthesized read of the highest-engagement posts about MorphoSys on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See MorphoSys on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles